UCB entered a $2.2 billion agreement to acquire Candid Therapeutics, while Celcuity reported positive Phase 3 results for its experimental breast cancer drug gedatolisib in PIK3CA mutant patients. The first ODAC meeting without longtime oncology leader Richard Pazdur spotlighted trial design challenges for AstraZeneca's camizestrant. In regulatory news, the Supreme Court restored mail ordering of mifepristone, reversing a federal appeals court's stay on the abortion pill.
What to Watch
The post-Pazdur ODAC's skepticism toward biomarker-triggered switching designs may force sponsors to rethink adaptive trial strategies; watch for whether FDA guidance evolves to address these "conceptual challenges" in future oncology submissions. Celcuity's two positive Phase 3 regimens in PIK3CA mutant breast cancer could accelerate NDA timelines, with FDA pre-submission meetings the next milestone. The Supreme Court's restoration of mail-order mifepristone access may influence future litigation around FDA approval authority for controversial therapies. Odyssey's $205M IPO will test market appetite for oncology stories; a successful pricing could unlock exits for venture-backed companies.
